Among patients with bacteremia caused by Gram-negative bacteria, we found no differences in abnormal INR, other adverse effects, or all-cause mortality between patients receiving CFP–SUL 1 g/1 g Q12H and CFP–SUL 2 g/2 g Q12H. The gene discussed is CFP; the disease is bacterial infectious disease with sepsis.